Whalesbook
Anuh Pharma Ltd has officially stated it will not qualify as a 'Large Corporate' (LC) under SEBI regulations for the financial year 2026-27. The company confirmed it did not meet the key criteria set by the Securities and Exchange Board of India. These requirements include having Rs. 1,000 crore or more in outstanding long-term borrowings and maintaining a credit rating of 'AA' or higher.
According to company filings, Anuh Pharma's total debt stood at Rs. 10.9 crore as of March 31, 2025, far below the Rs. 1,000 crore threshold. Furthermore, its credit rating from ICRA has typically been around '[ICRA]A-', which falls short of the 'AA' rating mandated by SEBI for LC status.
This non-classification means Anuh Pharma is exempt from specific obligations designed for large corporates to bolster the corporate bond market. These include mandatory fundraising targets through debt securities and associated complex disclosures. The company will continue to adhere to standard SEBI regulations applicable to entities not designated as LCs.
Anuh Pharma, part of the SK Group, is a manufacturer of Active Pharmaceutical Ingredients (APIs). While focusing on its core operations, the company has faced regulatory scrutiny in the past. Notably, it experienced an EDQM suspension for certain products in FY17, highlighting the importance of regulatory compliance in its key markets.
The company's scale is considerably smaller than major Indian pharmaceutical players like Sun Pharmaceutical Industries, Divi's Laboratories, and Cipla, which would likely fall under the 'Large Corporate' designation due to their substantial market capitalization and borrowing capacity. Investors will be monitoring Anuh Pharma for any significant shifts in its long-term borrowing levels, credit rating changes, and continued adherence to regulatory requirements as it pursues operational growth.